Alder files for $115M IPO

|By:, SA News Editor

Alder Biopharmaceuticals has filed to raise up to $115M in an IPO on Nasdaq.

The company develops anti-bodies for treating a range of conditions, and its pipeline includes Clazakizumab, which the the company is developing with Bristol-Myers Squipp for Rheumatoid Arthritis, and ALD403 for migraines.

Alder posted losses of $20.6M in 2013.

The company intends to trade under the ticker symbol ALDR.